Evolus, INC Schedule 13G passive stakes

The Vanguard Group has amended its Schedule 13G filing for Evolus Inc., reporting zero beneficial ownership following an internal realignment.

Timothy P. Lynch has disclosed a 9.9% beneficial ownership stake in Evolus, Inc., holding 6,425,726 shares of common stock.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, filed an amended Schedule 13G disclosing a shared beneficial ownership of 8.85% in Evolus, Inc. common stock.

Caligan Partners LP and David Johnson have reported a 6.4% beneficial ownership stake in Evolus, Inc., totaling 4,138,943 shares of common stock.

Timothy P. Lynch has increased his beneficial ownership in Evolus, Inc. to 7.9% of the common stock, totaling 5,133,776 shares.

Timothy P. Lynch has disclosed a 6.3% beneficial ownership stake in Evolus, Inc. common stock.

Perceptive Advisors and its affiliates have reduced their beneficial ownership in Evolus, Inc. to 3.8% of outstanding common stock.

Caligan Partners LP and David Johnson have disclosed a 5.2% beneficial ownership stake in Evolus, Inc., totaling 3,341,970 shares of common stock.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 5.90% in Evolus, Inc.'s common stock as of March 31, 2025.

Perceptive Advisors LLC and its affiliates have filed an amended Schedule 13G, reporting a continued passive beneficial ownership of 6.4% in Evolus, Inc.'s common stock.

Tang Capital Management, LLC and its affiliates, including Kevin Tang, have filed an amended Schedule 13G disclosing a collective beneficial ownership of 7.9% of Evolus, Inc.'s common stock as of March 31, 2025.

Medytox Inc., a South Korean company, has filed an amended Schedule 13G disclosing a 3.4% beneficial ownership stake in Evolus, Inc. as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.9% passive beneficial ownership stake in Evolus Inc. as of December 31, 2024.